Table 1.
Demographics, outcomes, and management of adverse events
| Patient ID | Age, sex | Disease location | Systemic disease at time of CAR T-cell treatment | No. of previous lines of therapy | Previous auto-HCT | Bridging WBRT, total dose (cGy) (fractions) | Systemic status before CAR T-cell therapy | Product | Day 28 systemic response | MRD status at day 28 | CRS, grade, treatment | ICANS and grade | Treatment of ICANS | Relapse, day of assessment | Current status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 47, M | LMD | Yes | 4 | Yes | No | CR | Axi-cel | CR | Negative | Yes, 1, tocilizumab | No | NA | No, day 91 | Alive with CR at day 91 |
| CR (LP negative)* | CR† | ||||||||||||||
| 2 | 72, F | Parenchyma | No | 4 | No | Yes, 2800 (14) | PD | Axi-cel | CR | Negative | Yes, 1, none | Yes, 3 | Solumedrol pulse and dexamethasone taper | No, day 129 | Alive with CR at day 129 |
| SD (MRI after RT) * | CR (LP and MRI)† | ||||||||||||||
| 3 | 42, F | Parenchyma | No | 4 | No | Yes, 2340 (13) | CR | Tisa-cel | CR | NA | Yes, 3, tocilizumab and dexamethasone taper | Yes, 1 | Dexamethasone | No, day 219 | Alive with CR at day 219 |
| PR (MRI after RT) * | CR (MRI) † | ||||||||||||||
| 4 | 39, F | LMD | Yes | 2 | No | No | PD | Axi-cel | CR | NA | Yes, 2, tocilizumab and dexamethasone | Yes, 2 | Dexamethasone taper | Yes, day 51 | Dead as a result of PD, day 109 |
| PD (LP positive)* | CR (LP)† | ||||||||||||||
| 5 | 50, M | Parenchyma | No | 4 | Yes | Yes, 4000 (20) | PD | Tisa-cel | CR | Negative | No | No | NA | Yes, day 83 | Dead as a result of PD, day 133 |
| PR (MRI after RT) * | CR (LP) † | ||||||||||||||
| 6 | 72, M | Parenchyma | No | 2 | No | Yes, 400 (2) | PD | Tisa-cel | PD | NA | No | No | NA | Yes, day 28 | Dead as a result of PD, day 63 |
| PD (MRI before RT) * ‡ | PD (MRI) † | ||||||||||||||
| 7 | 51, M | Parenchyma | Yes | 3 | No | Yes, 3000 (18) | PD | Tisa-cel | CR | Negative | No | No | No | No, day 48 | Alive with CR, day 48 |
| PR (MRI after RT) * | CR (MRI) † |
Patients who received WBRT are shown in bold.
Auto-HCT, autologous hematopoietic cell transplantation; Axi-cel, axicabtagene ciloleucel; CRS, cytokine release syndrome; F, female; LMD, leptomeningeal disease; LP, lumbar puncture; M, male; MRD, minimal residual disease; MRI, magnetic resonance imaging; NA, not applicable or not available; PD, progressive disease; PR, partial response; RT, radiation thereapy; SD, stable disease; Tisa-cel, tisagenlecleucel.
*
CNS status before CAR T-cell therapy (assessment study).
†
Day 28 CNS response (assessment study).
‡
Had PD before CAR T-cell infusion; received 2 Gy × 2 of WBRT; response was assessed after day 28.